Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

Diabetes Obes Metab · 2018 · PMC5969082 · PMID 29316164

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

12 , 13 Recently, the Exenatide Study of Cardiovascular Event Lowering (EXSCEL), which examined the cardiovascular effects of exenatide once‐weekly treatment vs usual care, found that exenatide once weekly did not increase cardiovascular risk, while also demonstrating a consistent safety profile 14 ; however, the recorded 9% decrease in cardiovascular events did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.